23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

March 20, 2024

https://www.globenewswire.com/news-release/2024/03/20/2849267/0/en/23andMe-Initiates-Phase-1-Clinical-Trial-for-its-Dual-Mechanism-Antibody-23ME-01473-Targeting-ULBP6.html

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq:ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors. The target for the new investigational antibody, ULBP6, was discovered through 23andMe’s proprietary research platform, the world’s largest recontactable database of de-identified human genetic and phenotypic information. This is the third drug target genetically validated by the 23andMe research platform to enter the clinic in under 4 years.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.